Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
et al., Nutrients, doi:10.3390/nu13082559
, Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics, Nutrients, doi:10.3390/nu13082559
Retrospective 288 hemodialysis patients in Spain, 137 with existing vitamin D treatments (94 with paricalcitol), showing lower mortality with treatment. There was no significant difference in outcomes based on serum levels, however authors do not separate patients that received vitamin D treatment.
|
risk of death, 50.1% lower, HR 0.50, p = 0.02, treatment 16 of 94 (17.0%), control 65 of 191 (34.0%), NNT 5.9, adjusted per study, paricalcitol treatment, multivariate Cox regression.
|
|
risk of death, 50.7% lower, HR 0.49, p = 0.003, all vitamin D derivatives, univariate.
|
|
risk of death, 7.7% higher, OR 1.08, p = 0.81, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses:
many patients received vitamin D treatment.
|
|
risk of mechanical ventilation, 47.5% lower, OR 0.53, p = 0.56, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses:
many patients received vitamin D treatment.
|
|
risk of ICU admission, 12.2% lower, OR 0.88, p = 0.87, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses:
many patients received vitamin D treatment.
|
|
risk of hospitalization, 0.8% lower, OR 0.99, p = 0.98, high D levels 50, low D levels 110, >30 vs. <20ng/ml, RR approximated with OR, outcome based on serum levels, excluded in exclusion analyses:
many patients received vitamin D treatment.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Jimenez et al., 26 Jul 2021, retrospective, Spain, peer-reviewed, 21 authors, study period 12 March, 2020 - 21 May, 2020, dosage paricalcitol 0.9μg weekly.
Abstract: nutrients
Article
Mortality in Hemodialysis Patients with COVID-19, the Effect
of Paricalcitol or Calcimimetics
María Dolores Arenas Jimenez 1,2, *, Emilio González-Parra 3 , Marta Riera 1 , Abraham Rincón Bello 4 ,
Ana López-Herradón 4 , Higini Cao 1 , Sara Hurtado 4 , Silvia Collado 1 , Laura Ribera 4 , Francesc Barbosa 1 ,
Fabiola Dapena 5 , Vicent Torregrosa 6 , José-Jesús Broseta 5 , Carlos Soto Montañez 6 ,
Juan F. Navarro-González 7,8,9 , Rosa Ramos 4 , Jordi Bover 10 , Xavier Nogués-Solan 11 , Marta Crespo 1 ,
Adriana S. Dusso 12,13 and Julio Pascual 1
1
2
3
4
5
Citation: Arenas Jimenez, M.D.;
González-Parra, E.; Riera, M.; Rincón
Bello, A.; López-Herradón, A.; Cao,
6
7
8
9
H.; Hurtado, S.; Collado, S.; Ribera, L.;
Barbosa, F.; et al. Mortality in
10
Hemodialysis Patients with
11
COVID-19, the Effect of Paricalcitol or
Calcimimetics. Nutrients 2021, 13,
12
2559. https://doi.org/10.3390/
nu13082559
Academic Editor: Andrea Fabbri
Received: 22 June 2021
Accepted: 20 July 2021
Published: 26 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
13
*
Department of Nephrology, Hospital del Mar, IMIM Hospital del Mar Medical Research Institute,
RD16/0009/0013 (ISCIII FEDER REDinREN), 08003 Barcelona, Spain; mriera1@imim.es (M.R.);
hcao@psmar.cat (H.C.); scollado@psmar.cat (S.C.); fbarbosa@psmar.cat (F.B.); mcrespo@psmar.cat (M.C.);
julpascual@gmail.com (J.P.)
Fundación Renal Iñigo Alvarez de Toledo, 28003 Madrid, Spain
Fundación Jimenez Díaz, 28040 Madrid, Spain; egonzalezpa@senefro.org
Fresenius Medical Care, Dirección Médica FMC, 28760 Madrid, Spain; abraham.rincon@fmc-ag.com (A.R.B.);
ana.lopez@fmc-ag.com (A.L.-H.); sara.hurtado@fmc-ag.com (S.H.); laura.ribera@fmc-ag.com (L.R.);
rosa.ramos@fmc-ag.com (R.R.)
Department of Nephrology, Consorci Sanitari Alt Penedes Garraf, 08800 Barcelona, Spain;
proyectologos1@gmail.com (F.D.); jjbroseta@clinic.cat (J.-J.B.)
Department of Nephrology and Kidney Transplantation, Hospital Clinic, 08036 Barcelona, Spain;
VTORRE@clinic.cat (V.T.); csoto@csg.cat (C.S.M.)
Research Division and Department of Nephrology, Hospital Nuestra Señora de la Candelaria,
38010 Santa Cruz de Tenerife, Spain; jnavgon@gobiernodecanarias.org
Instituto de Tecnologías Biomédicas, Universidad de La Laguna, 38010 Tenerife, Spain
Red de Investigación Renal (REDINREN–RD16/0009/0022), Instituto de Salud Carlos III,
28029 Madrid, Spain
Department of Nephrology, Hospital Can Ruti, 08916 Barcelona, Spain; jbover@fundacio-puigvert.es
Department of Internal Medicine, Hospital del Mar, Institut Mar for Medical Research, CIBERFES,
08003 Barcelona, Spain; xnogues@psmar.cat
Bone and Mineral Research Unit, Instituto de Investigaciones Sanitarias del Principado de Asturias,
33011 Oviedo, Spain; adriana.dusso@gmail.com
Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research,
Washington University School of Medicine, St. Louis, MO 63110, USA
Correspondence: lola@olemiswebs.net
Abstract: Background. In COVID-19 patients, low serum vitamin D (VD) levels have been associated
with severe acute respiratory failure and poor prognosis. In regular..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.